Biogen Inc. [NASDAQ: BIIB] traded at a low on 06/08/20, posting a -1.78 loss after which it closed the day’ session at $301.26. The results of the trading session contributed to over 1490713 shares changing hands. Over the past one week, the price volatility of Biogen Inc. stands at 2.15% while the volatility over the past one month is 2.84%.
The market cap for BIIB stock reached $52.06 billion, with 172.80 million shares outstanding and 164.86 million shares in the current float. Compared to the average trading volume of 1.95M shares, BIIB reached a trading volume of 1490713 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Biogen Inc. [BIIB]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BIIB shares is $318.82 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BIIB stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Biogen Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on April 23, 2020. While these analysts kept the previous recommendation, Citigroup dropped their target price from $365 to $240. The new note on the price target was released on April 23, 2020, representing the official price target for Biogen Inc. stock.
The Average True Range (ATR) for Biogen Inc. is set at 8.25, with the Price to Sales ratio for BIIB stock in the period of the last 12 months amounting to 3.61. The Price to Book ratio for the last quarter was 4.15, with the Price to Cash per share for the same quarter was set at 22.34. Price to Free Cash Flow for BIIB in the course of the last twelve months was 7.86 with Quick ratio for the last quarter at 1.50.
How has BIIB stock performed recently?
Biogen Inc. [BIIB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.06. With this latest performance, BIIB shares dropped by -4.06% in over the last four-week period, additionally plugging by 0.62% over the last 6 months – not to mention a rise of 32.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BIIB stock in for the last two-week period is set at 45.26, with the RSI for the last a single of trading hit 44.74, and the three-weeks RSI is set at 47.27 for Biogen Inc. [BIIB]. The present Moving Average for the last 50 days of trading for this stock 309.94, while it was recorded at 302.62 for the last single week of trading, and 286.73 for the last 200 days.
Biogen Inc. [BIIB]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Biogen Inc. [BIIB] shares currently have an operating margin of +45.85 and a Gross Margin at +80.97. Biogen Inc.’s Net Margin is presently recorded at +46.32.
Return on Total Capital for BIIB is now 30.09, given the latest momentum, and Return on Invested Capital for the company is 31.67. Return on Equity for this stock inclined to 44.64, with Return on Assets sitting at 22.42. When it comes to the capital structure of this company, Biogen Inc. [BIIB] has a Total Debt to Total Equity ratio set at 48.27. Additionally, BIIB Total Debt to Total Capital is recorded at 32.56, with Total Debt to Total Assets ending up at 23.65. Long-Term Debt to Equity for the company is recorded at 36.51, with the Long-Term Debt to Total Capital now at 24.62.
Reflecting on the efficiency of the workforce at the company, Biogen Inc. [BIIB] managed to generate an average of $795,743 per employee. Receivables Turnover for the company is 5.13 with a Total Asset Turnover recorded at a value of 0.48.Biogen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.50 and a Current Ratio set at 1.70.
Earnings analysis for Biogen Inc. [BIIB]
With the latest financial reports released by the company, Biogen Inc. posted 9.15/share EPS, while the average EPS was predicted by analysts to be reported at 7.53/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 21.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BIIB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Biogen Inc. go to 0.90%.
Insider trade positions for Biogen Inc. [BIIB]
There are presently around $44,674 million, or 89.90% of BIIB stock, in the hands of institutional investors. The top three institutional holders of BIIB stocks are: BLACKROCK INC. with ownership of 16,043,037, which is approximately 2.455% of the company’s market cap and around 0.10% of the total institutional ownership; PRIMECAP MANAGEMENT CO/CA/, holding 15,965,989 shares of the stock with an approximate value of $4.9 billion in BIIB stocks shares; and VANGUARD GROUP INC, currently with $4.37 billion in BIIB stock with ownership of nearly 2.651% of the company’s market capitalization.
Positions in Biogen Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 441 institutional holders increased their position in Biogen Inc. [NASDAQ:BIIB] by around 9,970,148 shares. Additionally, 580 investors decreased positions by around 16,038,370 shares, while 189 investors held positions by with 119,640,890 shares. The mentioned changes placed institutional holdings at 145,649,408 shares, according to the latest SEC report filing. BIIB stock had 108 new institutional investments in for a total of 1,208,344 shares, while 103 institutional investors sold positions of 1,044,752 shares during the same period.